Novus therapeutics, inc. (NVUS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13
Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

Operating expenses
Research and development

1,648

1,333

1,509

2,297

2,989

2,740

1,651

1,329

1,097

493

517

533

479

-6,385

1,053

592

7,931

7,733

8,491

5,855

10,559

3,804

2,825

4,392

3,556

2,704

General and administrative

1,730

967

1,411

1,792

1,886

1,837

1,848

1,860

1,698

1,612

2,448

6,133

906

-2,516

564

340

3,549

3,339

3,416

3,127

2,741

2,457

3,599

1,493

1,336

661

Total operating expenses

3,378

4,167

2,920

4,089

4,875

4,577

3,499

3,189

2,795

2,105

2,965

6,666

1,385

-8,901

1,617

932

11,480

11,072

11,907

8,982

13,300

6,261

6,424

5,885

4,892

3,365

Loss from operations

-3,378

-4,167

-2,920

-4,089

-4,875

-4,577

-3,499

-3,189

-2,795

-2,105

-2,965

-6,666

-1,385

8,901

-1,617

-932

-11,480

-11,072

-11,907

-8,982

-13,300

-6,261

-6,424

-5,885

-4,892

-3,365

Interest income and other income, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

54

-

54

25

-

-

-

34

45

-

Interest income and other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

40

-

-

-

-

-

Interest and other income (expense), net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

34

-

-

-

Other income (expense), net

30

23

27

-4

-6

3

3

0

-11

-5

-5

4

11

-

-418

-70

-

-

-

-

-

-

-

-

-

-

Warrant inducement expense

4,829

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-8,177

-4,144

-2,893

-4,093

-4,881

-4,574

-3,496

-3,189

-2,806

-2,110

-2,970

-6,662

-1,374

8,808

-2,035

-1,002

-11,426

-11,017

-11,853

-8,957

-13,260

-6,208

-6,390

-5,851

-4,847

-3,365

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,365

Net loss per share, basic and diluted

-0.47

-0.27

-0.22

-0.35

-0.52

-0.49

-0.37

-0.34

-0.36

0.04

-0.43

-1.32

-0.59

4.65

-4.35

-2.25

-0.51

-0.49

-0.53

-0.40

-0.59

20.58

-2.71

-11.68

-9.79

-6.82

Weighted-average common shares outstanding, basic and diluted

17,267

13,044

12,974

11,751

9,427

9,445

9,420

9,407

7,749

7,198

6,943

4,154

413

-21,253

81

77

22,625

22,590

22,540

22,421

22,384

22,523

2,357

501

495

493

Net loss

-8,177

-4,144

-2,893

-4,093

-4,881

-4,574

-3,496

-3,189

-2,806

-2,110

-2,970

-6,662

-1,374

8,808

-2,035

-1,002

-11,426

-11,017

-11,853

-8,957

-13,260

-6,208

-6,390

-5,851

-4,847

-3,365

Unrealized gains on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

-

10

-2

-

-

-

-

-

-

Total other comprehensive income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

50

-

10

-2

-

-

-

-

-

-

Total comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,376

-11,080

-11,843

-8,959

-13,260

-

-6,390

-5,851

-

-